Companies /Healthcare

Eterna Therapeutics Inc

NASDAQ: ERNA Biotechnology

$2.31

▼ $0.39 (−14.45%) today

Markets open · 2:28pm ET

ERNA at a Glance

Valuation

Market cap: $4.4M

Profitability

Revenue (TTM): $1,000
EPS (TTM): $-13.63

Price

52-week range: $3 – $48
Street target: $30.00

Earnings

Next report: Nov 6, 2026

Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: ERNA ernexatx.com

About Ernexa Therapeutics

Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. The company is headquartered in Brooklyn, New York.

ERNA Coverage

10:35am ET

Investing

Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners

President Trump’s 12-word remark, “I don’t think about Americans’ financial situation, I don’t think about anybody,” hit the wires, and the reaction showed up in the forgotten corners of the market, where…

ERNA HCWB MRNO

Alex Sirois

Frequently Asked Questions

What does Ernexa Therapeutics do?

Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. The company is headquartered in Brooklyn, New York.

What is the ERNA stock price target?

The Wall Street consensus 12-month price target for ERNA is $30.00.